Wockhardt enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


31,151	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
629	629	534	505	90.0
341	341	304	303	308
2,125	2,125	1,859	2,112	1,887
32,988	—	—	—	—
1,496	1,496	1,325	1,607	1,797
₹2,036.30	—	—	—	—

7,406	7,406	6,516	5,774	5,549
28.7%	28.7%	28.5%	36.6%	34.0%
0.06×	—	—	—	—

9.26×	—	—	—	—
42.73×	—	—	—	—
60.42×	—	—	—	—
129.87×	—	—	—	—
3,564	3,373	3,012	2,798	2,651
772	652	393	39.0	101
546	425	176	−184	−150
—	390	−22.0	219	153
254	254	−116	160	111
—	219	−116	160	110
—	136	94.0	59.0	42.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

WOCKPHARMA₹1,922.90

Wockhardt Ltd.

· Pharma & Health

₹ CrorePeersBIOCON SYNGENE ASTERDM GLAND PPLPHARMA COHANCE LALPATHLAB NATCOPHARMMcap ₹31,151 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	31,151.0
- Cash, Equiv & ST Investments	90.0	505.0	534.0	629.0	629.0
+ Minority Interest	308.0	303.0	304.0	341.0	341.0
+ Total Debt	1,887.0	2,112.0	1,859.0	2,125.0	2,125.0
Enterprise Value	—	—	—	—	32,988.0
Net Debt (memo)	1,797.0	1,607.0	1,325.0	1,496.0	1,496.0
EV per Share	—	—	—	—	2,036.30

Total Capital	5,549.0	5,774.0	6,516.0	7,406.0	7,406.0
Total Debt/Total Capital	34.01	36.58	28.53	28.69	28.69
Total Debt/EV	—	—	—	—	0.06

EV/Sales	—	—	—	—	9.26
EV/EBITDA	—	—	—	—	42.73
EV/EBIT	—	—	—	—	60.42
EV/Free Cash Flow	—	—	—	—	129.87
Reference Items — Trailing FY Values
Sales	2,651.0	2,798.0	3,012.0	3,373.0	3,564.0
EBITDA	101.0	39.0	393.0	652.0	772.0
EBIT	-150.0	-184.0	176.0	425.0	546.0
Operating Cash Flow	153.0	219.0	-22.0	390.0	—
Free Cash Flow	111.0	160.0	-116.0	254.0	254.0
FCFF (free cash flow to the firm)	109.5	160.0	-116.0	219.1	—
Capital Expenditure	42.0	59.0	94.0	136.0	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.